A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional

#209

Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.

Aim(s): To assess the proportion of patients preferring self/partner injections and to describe the impact on costs, efficacy and safety.

Materials and methods: Twenty-six patients with symptomatic NETs treated with a stable dose of Lanreotide Autogel, 90 or 120 mg, every four weeks were randomised to start with either self/partner or healthcare administration. After three injections, patients switched administration method. The total study duration for each patient was 7.5-8.5 months including 2-3 training injections.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Johanson V, Wilson B, Abrahamsson A, Jianu C, Calissendorff J,

Keywords: neuroendocrine tumors, NET, self-administration, somatostatin analogs, lanreotide,